Evidence map›Paper›PMID 37325322›Full record

ArticleFrontiers in public health2023

Additional challenges in reaching hepatitis C elimination goals in Germany due to the COVID-19 pandemic - descriptive analysis of drug prescription data from January 2018 to June 2021.

Emily D Meyer, Sandra Dudareva, Christian Kollan, Stefan Mauss, Heiner Wedemeyer, Daniel Schmidt, Ruth Zimmermann

Open access · goldAbstract read
In one paragraph

Article in Frontiers in public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Emily D MeyerDepartment of Infectious Disease Epidemiology, Postgraduate Training for Applied Epidemiology (PAE), Robert Koch Institute, Berlin, Germany.
Sandra DudarevaDepartment of Infectious Disease Epidemiology, Unit of HIV/AIDS, STI and Blood-borne Infections, Robert Koch Institute, Berlin, Germany.
Christian KollanDepartment of Infectious Disease Epidemiology, Unit of HIV/AIDS, STI and Blood-borne Infections, Robert Koch Institute, Berlin, Germany.
Stefan MaussCenter for HIV and Hepatogastroenterology, Düsseldorf, Germany.
Heiner WedemeyerDepartment of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hanover, Germany.
Daniel SchmidtDepartment of Infectious Disease Epidemiology, Unit of HIV/AIDS, STI and Blood-borne Infections, Robert Koch Institute, Berlin, Germany.
Ruth ZimmermannDepartment of Infectious Disease Epidemiology, Unit of HIV/AIDS, STI and Blood-borne Infections, Robert Koch Institute, Berlin, Germany.
Robert Koch Institute · DECenter for HIV and Hepatogastroenterology · DEMedizinische Hochschule Hannover · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Effectively treating hepatitis C viral (HCV) infections prevents sequelae and onward transmission. In Germany, HCV drug prescriptions have declined since 2015. During the COVID-19 pandemic, lockdowns impacted the access to HCV care services and HCV treatment. We assessed if the COVID-19 pandemic further decreased treatment prescriptions in Germany. We built log-linear models with monthly HCV drug prescription data from pharmacies from January 2018 - February 2020 (pre-pandemic) to calculate expected prescriptions for March 2020-June 2021 and different pandemic phases. We calculated monthly prescription trends per pandemic phase using log-linear models. Further, we scanned all data for breakpoints. We stratified all data by geographic region and clinical settings. The number of DAA prescriptions in 2020 (

Indexed as

COVID-19Hepatitis CAntiviral AgentsCommunicable Disease ControlDrug PrescriptionsGermanyGoalsHepacivirusHumansPandemicsAntiviral AgentsAgenda 2030antiviral agents - therapeutic useCOVID-19delivery of health carehepatitis C

Identifiers

PMID37325322
PMCPMC10267983
OpenAlexW4379055591

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.